Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455461 | 0.85 | TP53 (0.34) | GAATP53CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL16388406 | 0.75 | BRD4 (0.37) | TP53CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10246802 | 0.72 | CHRNB2 (0.35) | GAATP53CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL15251997 | 0.71 | TP53 (0.43) | GAATP53CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL15256234 | 0.71 | TP53 (0.43) | GAATP53CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL244740 | 0.69 | — | — | |
| SCHEMBL2948892 | 0.69 | TP53 (0.56) | GAATP53CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL2200767 | 0.69 | TP53 (0.56) | GAATP53CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL74396 | 0.69 | TP53 (0.56) | GAATP53CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL18527512 | 0.68 | CHRNB2 (0.40) | GAATP53CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |